Drug Type Monoclonal antibody |
Synonyms Anti-TGFb SAR-439459 |
Target |
Action inhibitors |
Mechanism TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Multiple Myeloma | Phase 2 | Italy | 25 Jan 2021 | |
Refractory Multiple Myeloma | Phase 2 | Israel | 25 Jan 2021 | |
Refractory Multiple Myeloma | Phase 2 | Norway | 25 Jan 2021 | |
Refractory Multiple Myeloma | Phase 2 | United States | 25 Jan 2021 | |
Refractory Multiple Myeloma | Phase 2 | Greece | 25 Jan 2021 | |
Refractory Multiple Myeloma | Phase 2 | Puerto Rico | 25 Jan 2021 | |
Refractory Multiple Myeloma | Phase 2 | Australia | 25 Jan 2021 | |
Refractory Multiple Myeloma | Phase 2 | Germany | 25 Jan 2021 | |
Refractory Multiple Myeloma | Phase 2 | France | 25 Jan 2021 | |
Refractory Multiple Myeloma | Phase 2 | Portugal | 25 Jan 2021 |
Phase 1 | 3 | tqvbnlaklz(xutkfwzmoq) = Two grade 3 treatment-related adverse events were reported: rash tpivlwbued (oeiexsxhrc ) View more | Negative | 28 Apr 2025 | |||
NCT03192345 (ASCO2022) Manual | Phase 1 | 109 | (Part 2A) | (rwfiulvsoz) = 100% of pts had at least one treatment emergent adverse event (AE), 67% were G≥3, 34% related G≥3, 17% G5, and 4% related G5. hubmmsvsav (kcxnskgujm ) View more | Negative | 02 Jun 2022 | |
(Part 2B) | |||||||
Phase 1 | Advanced Malignant Solid Neoplasm mesenchymal CRC | CMS4 phenotype | - | ydkbfwbpsq(hsnkovmkvu) = a trend of increased revppheyty (yphjubsgfn ) View more | - | 10 Nov 2021 | ||
Phase 1 | 52 | (yshaebycwv) = vvevhnllon quqxvdfvfn (uolmowqlwf ) View more | Positive | 20 May 2021 | |||
(yshaebycwv) = xzeuobbrec quqxvdfvfn (uolmowqlwf ) View more |